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Abstract
Objective The objective of this cross-sectional, observational study was to investigate the disease burden of myotonic dys-
trophy type 1 (DM1), a disabling muscle disorder.
Methods Adults with DM1 were recruited as part of the PhenoDM1 study from Newcastle University (Newcastle upon Tyne, 
UK). Disease burden data were recorded through the Individualized Neuromuscular Quality of Life (INQoL) questionnaire. 
Results were examined by sex and clinical variables [e.g. the six-minute walk test (6MWT), the Mini Mental State Examina-
tion, and estimated progenitor and modal allele CTG repeat length].
Results Our sample consisted of 60 patients with DM1 (mean age: 45 years; 45% female). Muscle weakness and fatigue 
constituted the two most common disease manifestations, reported by 93% and 90% of patients, respectively, followed by 
muscle locking (73%). Most patients (> 55%) reported feeling anxious/worried, depressed, frustrated, and/or having low 
confidence/self-esteem, 23% and 33% indicated substantial impairment of daily and leisure activities, respectively, and 47% 
did not work as a consequence of the disease. Estimated progenitor CTG length corrected by age correlated surprisingly 
well with INQoL scores. Differences by sex were generally minor.
Conclusion We show that DM1 is associated with a substantial disease burden resulting in impairment across many differ-
ent domains of patients’ lives, emphasizing the need for a holistic approach to medical management. Our results also show 
that the INQoL records relevant information about patients with DM1, but that further investigation of the psychometric 
properties of the scale is needed for meaningful interpretation of instrument scores.
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Introduction
Myotonic dystrophy type 1 (DM1) is a chronic, progres-
sive, and disabling muscle disorder frequently involv-
ing other organ systems [1]. The disease is inherited in 
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a cytosine–thymine–guanine (CTG) triplet repeat in the 
DMPK gene, and represents the most common muscular 
dystrophy in adults with an estimated prevalence in Europe 
of between 10–18/100,000 [2]. Patients with DM1 typically 
experience muscle weakness and locking (i.e. myotonia), but 
the phenotypic spectrum is wide and symptoms are variable, 
which makes the identification and validation of suitable 
outcome measures for clinical research challenging [3].
The disease burden of DM1 has been investigated in sev-
eral geographical settings using different study designs and 
rating-scales, including the Individualized Neuromuscular 
Quality of Life (INQoL), a patient-reported outcome (PRO) 
tool developed to measure the impact of neuromuscular dis-
ease on various aspects of patients’ life [4]. However, to 
date, no study has examined specific components of the dis-
ease burden of DM1 using the INQoL in a UK setting. The 
objective of this study was therefore to estimate the preva-
lence, severity, and difficulties of symptoms of DM1, the 
impact of the disease on daily, leisure, and work activities, 
patients’ independence and relationships, as well as emo-
tional well-being and appearance as recorded through the 
INQoL in adult patients with DM1 from the UK.
Materials and methods
Study design and patient sample
The data reported as part of this work were collected in 
the Myotonic Dystrophy Type 1 Deep Phenotyping to 
Improve Delivery of Personalized Medicine and Assist 
in the Planning, Design and Recruitment of Clinical Tri-
als (PhenoDM1) study (ClinicalTrials.gov identifier: 
NCT02831504). Patients with DM1 were identified and 
recruited from the specialist neuromuscular clinic at New-
castle University (Newcastle upon Tyne, UK). To be eligible 
to participate, patients were required to meet the following 
inclusion criteria: (i) ≥ 18 years of age, (ii) genetically con-
firmed diagnosis of DM1, (iii) able and willing to provide 
written informed consent to participate in the study, and (iv) 
ability to perform the 10 m walking test at selected pace 
without any assistance (walking devices allowed). Patients 
with congenital DM were not included in the study. To fur-
ther minimize reporting bias, incomplete questionnaires or 
questionnaires with double answers were excluded. Study 
ethical approval was granted by the Newcastle and North 
Tyneside Ethics Committee (reference: NE/15/0178).
Study procedures, outcomes, and genetic analysis
The disease burden data presented as part of this work were 
recorded directly from patients through the INQoL as part of 
their routine clinical follow-up. The INQoL encompasses a 
total of 45 questions covering the prevalence and impact of a 
set of common muscle disease symptoms [muscle weakness, 
muscle locking (i.e. myotonia), pain, fatigue, droopy eyelids 
(i.e. ptosis), double vision (i.e. diplopia), and swallowing 
difficulties (i.e. dysphagia)], the impact of muscle disease 
on daily, leisure, and work activities, patients’ independ-
ence, relationships, emotional well-being, and appearance 
(i.e. “looks”) [4]. In addition to descriptive analysis of the 
collected data, each item within the INQoL is scored on a 
seven-point Likert scale (ranging from 0 to 6, or 1 to 7), 
where a higher score represents a higher disease burden, 
and a total instrument score can also be calculated based 
on the outcomes of five subscales [4]. As part of the study 
procedures, we also recorded data from patients concern-
ing their basic demographic and clinical characteristics, as 
well as results from the six-minute walk test (6MWT) and 
the Mini Mental State Examination (MMSE). The 6MWT 
was performed in a 25-m long corridor with input every 
minute following the agreed procedures at the third outcome 
measures in myotonic dystrophy type 1 (OMMYD-3) inter-
national workshop [3]. CTG repeat length was estimated 
from blood DNA by the small-pool PCR assay as described 
by Gomes-Pereira et al. [5] using the CTG repeat-flanking 
primers DM-C and DM-DR [6, 7]. Replicate reactions 
were separated by gel electrophoresis, Southern blotted 
and hybridised using a 32P-labelled 56 x CTG repeat probe. 
Bands were detected by autoradiography and sized by com-
parison against the DNA molecular weight marker, using 
CLIQS software (TotalLab UK Ltd.). The bottom edge of 
the expanded allele bands was used to determine the esti-
mated progenitor allele length (ePAL), i.e. the number of 
CTG repeats inherited [7]. The densest part of the expanded 
allele bands was used to estimate the modal allele length at 
the time of DNA sampling.
Statistical analysis
We calculated the distribution of replies [i.e. the proportion 
and a corresponding 95% confidence interval (CI)] across all 
items and levels within the INQoL. We also derived the pro-
portion of patients at or above two specific level thresholds 
(i.e. the first level, and the three highest levels, respectively) 
to facilitate interpretation and investigate the proportion of 
patients with, e.g. no difficulties, and a considerable amount, 
very many, or an extreme amount of difficulties. In addition, 
we calculated mean scores for each item/domain, as well 
as the total score as described by Vincent et al. [4], for the 
total sample, and by sex. We compared the distribution of 
replies to INQoL items and instrument scores across strata 
using Welch t tests and Welch’s analysis-of-variance models. 
In addition, we estimated Pearson’s correlation coefficients 
to investigate the relationship between DM1 symptoms and 
amount and importance of difficulties, as well as INQoL 
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scores, and CTG repeat length, 6MWT, and MMSE, respec-
tively. Finally, to further explore the relationship between 
estimated progenitor CTG repeat length and INQoL scores, 
we fitted ordinary least squares regression models to the 
study data, with INQoL scores as dependent variables and 
estimated progenitor CTG repeat length and age, as well as 
an interaction variable between estimated progenitor CTG 
repeat length and age, as independent variables [7]. Esti-
mated progenitor CTG repeat length was normalised by log 
transformation [7]. All analyses were conducted in Stata 14 
or R.
Results
The final sample consisted of n = 60 patients with DM1 who 
completed all sections of the INQoL in accordance with the 
instructions. These patients constituted a subset of the total 
PhenoDM1 study population (n = 110) who were invited, and 
subsequently agreed, to complete the INQoL as part of the 
study procedures (in addition to the clinical and genetic tests 
performed). Summary demographic and clinical character-
istics of the study cohort are presented in Table 1. Age at 
baseline ranged between 18 and 77 years, age at first symp-
toms of DM1 between 0 and 65 years, 6MWT result between 
10 and 693 meters, MMSE score between 16 and 30, esti-
mated progenitor length between 58 and 592 CTG repeats, 
and modal allele length between 64 and 1290 CTG repeats. 
At baseline, approximately 15% of patients had pacemakers, 
27% history of cataract surgery, and 13% received part-time 
ventilation support. In our sample, women with DM1 had 
fewer years of full-time education (13 vs. 15, p = 0.037) and 
were to a greater extent in a relationship or married (70% 
vs. 36%, p = 0.008) compared with men. No other significant 
differences in reported demographic or clinical characteris-
tics were noted by sex.
Prevalence, severity, and difficulties of symptoms 
of DM1
The INQoL records data on three aspects of common 
neuromuscular disease symptoms: (i) the prevalence 
and severity of symptoms, (ii) the amount of difficulties 
caused by the symptoms, and (iii) the importance of dif-
ficulties caused by symptoms. Prevalence of symptoms of 
DM1 as recorded using the INQoL is presented in Fig. 1. 
Muscle weakness and fatigue constituted the two most 
common disease manifestations, reported by 93% (95% 
CI 84–98%) and 90% (79–96%) of patients, respectively, 
followed by muscle locking (73%; 60–84%), swallowing 
difficulties (73%; 60–84%), pain (67%; 53–78%), droopy 
eyelids (60%; 46–72%), and double vision (18%; 9–30%). 
Moreover, 47% (34–60%) of patients stated that they 
experienced a considerable amount, a lot, or an extreme 
amount of muscle weakness. The corresponding estimates 
for fatigue were 32% (20–45%), muscle locking 18% 
(10–30%), swallowing difficulties 15% (7–27%), pain 15% 
(7–27%), droopy eyelids 10% (4–21%), and double vision 
0% (0–6%), respectively.
The amount of difficulties caused by symptoms as 
recorded using the INQoL is presented in Fig. 2. In total, 
42% (29–55%) of patients reported that they experienced a 
considerable amount, very many or an extreme amount of 
difficulties with muscle weakness in their lives. The corre-
sponding estimates for muscle locking were 18% (10–30%), 
pain 18% (10–30%), fatigue 28% (17–41%), droopy eyelids 
5% (1–14%), double vision 2% (0–9%), and difficulties with 
swallowing 10% (4–21%), respectively.
The importance to patients of difficulties caused by 
symptoms recorded using the INQoL is presented in Fig. 3. 
In total, 47% (34–60%) of patients reported that difficul-
ties caused by muscle weakness were considerably, very, or 
extremely important to them. The corresponding estimates 
for muscle locking were 22% (12–34%), pain 22% (12–34%), 
fatigue 35% (23–48%), droopy eyelids 10% (4–21%), double 
vision 3% (0–12%), and difficulties with swallowing 23% 
(13–36%), respectively.
Impact of DM1 on daily, leisure, and work activities
In total, 23% (13–36%) of patients reported that their abil-
ity to perform daily activities (e.g. washing, dressing, and 
housework) was considerably, very much, or extremely 
affected by DM1. The corresponding estimates for leisure 
Table 1  Demographic and clinical characteristics of the study sample
Data presented as n (%), if not specified otherwise. Total sample: 
n = 60, excluding missing values for n = 2 patients (*) and n = 1 
patient (**)
Age, mean (SD) years 45 (14)
Sex, female 27 (45%)
Age at first symptoms, mean (SD) years* 23 (16)
Part-time wheelchair dependency 9 (15%)
Six-minute walk test result, mean (SD) meters** 412 (151)
Mini Mental State Examination, mean (SD) score 29 (2)
Estimated progenitor CTG repeat length, mean (SD)* 239 (126)
Modal CTG repeat length, mean (SD)* 489 (267)
Education, mean (SD) years completed* 14 (3)
Married or in a relationship 29 (48%)
Current occupation
 Employed 15 (25%)
 Retired 8 (13%)
 Long-term sick leave 20 (33%)
 Unemployed/other 17 (28%)
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activities were 33% (22–47%). Moreover, 62% (48–74%) 
of patients had no paid employment; 47% (34–60%) due to 
the disease. Among patients with paid employment, 13% 
(6–25%) reported that their work activities were consider-
ably, very much, or extremely affected by DM1.
Impact of DM1 on patients’ independence 
and relationships
Concerning help from other people in carrying out daily 
activities, in total, 27% (16–40%) of patients reported that 
they do not need any assistance. In contrast, 33% (22–47%) 
of patients reported that they need a considerable amount, 
very much, or an extreme amount of assistance, 32% 
(20–45%) rated their level of independence as quite bad, 
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Fig. 1  Prevalence of symptoms of DM1 as recorded using the INQoL. The Individualized Neuromuscular Quality of Life (INQoL) questionnaire
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Fig. 2  Amount of difficulties caused by symptoms as recorded using the INQoL. The Individualized Neuromuscular Quality of Life (INQoL) 
questionnaire
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bad, or the worst it could possibly be, 48% (35–62%) stated 
that the lack of independence was considerably, very, or 
extremely important to them, and only 3% (0–12%) that their 
level of independence was exactly as they would like it to be.
Figure 4 shows difficulties in relationships caused by 
DM1. In total, 52% (38–65%) of patients were in a relation-
ship, and of them, 48% (30–67%) reported that their dis-
ease did not cause any difficulties for their partner/spouse, 
and 10% (2–26%) that it resulted in a considerable amount, 
very many, or an extreme amount of difficulties. The cor-
responding estimates for other family members were 47% 
(34–60%) and 3% (0–12%), friends 43% (31–57%) and 3% 
(0–12%), and other people (e.g. strangers, acquaintances, 
and colleagues) 32% (20–45%) and 18% (10–30%), respec-
tively. Yet, across the four categories, only 8% (3–18%), 7% 
(2–16%), and 5% (1–14%), respectively, indicated that their 
close family friendships, close friendships, and relationships 
with other people were exactly as they would like.
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Fig. 3  Importance of difficulties caused by symptoms as recorded using the INQoL. The Individualized Neuromuscular Quality of Life (INQoL) 
questionnaire
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Fig. 4  Relationship difficulties caused by DM1 as recorded using the INQoL. The Individualized Neuromuscular Quality of Life (INQoL) ques-
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Impact of DM1 on emotional well‑being 
and appearance
In total, 68% (55–80%) of patients reported feeling anxious/
worried, and 15% (7–27%) to a substantial degree (i.e. con-
siderably, very much, or extremely). The corresponding esti-
mates for depressive feelings were 55% (42–68%) and 13% 
(6–25%), for frustration 68% (55–80%) and 30% (19–43%), 
and for low confidence/self-esteem 77% (64–87%) and 
35% (23–48%), respectively. Concerning appearance, 18% 
(10–30%) of patients reported no impact of DM1 on their 
looks, and 25% (15–38%) that their looks were considerably, 
very much, or extremely affected by the disease. Yet, only 
10% (4–21%) stated that appearance was important to them, 
and of these, 40% (28–53%) considerably, very, or extremely 
important.
INQoL instrument scores
INQoL domain and total scores, where a higher score rep-
resents a higher disease burden, are presented in Table 2.
Relationship between DM1 symptoms and amount 
and importance of difficulties
The amount of muscle weakness, pain, fatigue, muscle 
locking, droopy eyelids, double vision, and swallowing dif-
ficulty, respectively, was all significantly associated with the 
amount of difficulties caused by each symptom (all ρ > 0.73, 
p < 0.001), and the amount of difficulties was associated with 
the importance of difficulties (all ρ > 0.76, p < 0.001).
Relationship between sex and disease burden 
of DM1
We identified no significant differences between women and 
men with DM1 concerning the crude overall prevalence of 
symptoms (all p > 0.189), but found that a larger proportion 
of women with DM1 experienced a considerable amount, lot 
or, an extreme amount of fatigue (48% vs. 18%, p = 0.015) 
and depressive feelings (26% vs. 3%, p = 0.017). In addition, 
there was a trend that a larger proportion of women rated the 
importance of difficulties associated with fatigue as consid-
erably, very, or extremely (48% vs. 24%, p = 0.059). Con-
cerning impact on daily life, a larger proportion of men (59% 
vs. 30%, p = 0.025) reported that their muscle condition 
caused difficulties in their relationships with their friends, 
and more men than women rated their level of independence 
as quite bad, bad, or the worst it could possibly be (42% vs. 
19%, p = 0.044). No other significant differences in INQoL 
outcomes and scores were identified in our analyses by sex.
Relationship between clinical variables and INQoL 
scores
Results from our correlation analysis showed that estimated 
progenitor CTG repeat length was significantly associated 
with muscle weakness score (ρ = 0.38, p = 0.003) and inde-
pendence score (ρ = 0.34, p = 0.008), modal CTG repeat 
length with muscle weakness score (ρ = 0.44, p < 0.001) 
and independence score (ρ = 0.35, p = 0.008), MMSE 
with INQoL independence score (ρ = − 0.30, p = 0.021), 
and 6MWT with muscle weakness score (ρ = − 0.64, 
p < 0.001), pain score (ρ = − 0.38, p = 0.003), activities score 
(ρ = − 0.59, p < 0.001), independence score (ρ = − 0.53, 
p < 0.001), body image score (ρ = -0.30, p = 0.023), and total 
score (ρ = − 0.46, p < 0.001). No other significant differences 
were identified in our correlation analysis of clinical vari-
ables and INQoL scores. Finally, outcomes from our regres-
sion analysis showed that age and estimated progenitor CTG 
repeat length were able to explain a non-trivial proportion 
of the variance in several INQoL domains: muscle weak-
ness score (R2 = 0.21, p = 0.001), fatigue score (R2 = 0.09, 
p = 0.043), muscle locking score (R2 = 0.090, p = 0.038), 
activities score (R2 = 0.18, p = 0.003), independence 
score (R2 = 0.23, p < 0.001), relationship score (R2 = 0.10, 
p = 0.036), emotions score (R2 = 0.12, p = 0.021), and total 
score (R2 = 0.19, p = 0.002).
Discussion
To the best of our knowledge, this study represents the first 
comprehensive examination of the disease burden of DM1 
in the UK as recorded though the INQoL. Our results show 
Table 2  INQoL subscale and total scores
Data presented as mean (SD). A higher score resents a higher disease 
burden, and vice versa
a The total INQoL score was calculated as described by Vincent et al. 
[4]
Total (n = 60) Sex
Males (n = 33) Females (n = 27)
Muscle weakness 53 (28) 55 (30) 52 (26)
Muscle locking 32 (28) 31 (29) 32 (26)
Pain 30 (29) 27 (27) 34 (31)
Fatigue 48 (29) 43 (27) 55 (31)
Activities 46 (29) 47 (31) 44 (28)
Independence 41 (30) 41 (34) 40 (25)
Relationships 26 (19) 27 (20) 23 (19)
Emotions 34 (25) 30 (22) 40 (27)
Body image 42 (27) 41 (28) 42 (26)
Totala 45 (22) 45 (23) 45 (21)
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that the vast majority of affected patients suffer from some 
degree of muscle weakness, muscle locking, pain, fatigue, 
and difficulties with swallowing, and that these symptoms 
collectively have a non-trivial impact on their ability to per-
form activities of daily living. Indeed, in our sample, 23% 
of patients indicated that their leisure activities were con-
siderably, very much, or extremely affected by DM1, 47% 
did not work due to their illness, 33% reported requiring a 
considerable amount, very much, or an extreme amount of 
assistance, and 52% stated that their illness caused difficul-
ties in their relationship with their partner/spouse. Our data 
also show that DM1 is often associated with impairment 
in psychological well-being, including anxiety, depressive 
feelings, frustration, and low confidence/self-esteem. Taken 
together, these findings underscore the detrimental impact of 
DM1 on affected patients and highlight the substantial unmet 
medical need in this disease population.
In line with expectations and previous research [8–11], 
our INQoL results show that muscle weakness and fatigue 
constitute two of the most common manifestations of DM1, 
affecting the vast majority of patients. In addition, these 
symptoms were also found to be associated with the most 
difficulties to the patients. We identified no significant dif-
ferences concerning the crude prevalence of muscle weak-
ness by sex, but did find, in contrast to previous research 
[12] that a significantly larger proportion of women (48% 
vs. 18%) experienced a considerable amount, a lot, or an 
extreme amount of fatigue.
Considering emotional well-being in DM1, most patients 
in our sample reported feeling anxious/worried, depressed, 
and/or frustrated to some degree, and many also indicated 
low confidence/self-esteem. Data indicating impaired mental 
health in DM1 have been previously reported [8–10, 13–16]. 
Interestingly, in the present study, we found evidence sug-
gesting that women with DM1 were much more likely to 
report depressive feelings than men, a result also noted in 
previous research [8]. Yet, as discussed by Peric et al. [15], 
it is not known if these psychological traits constitute symp-
toms or manifestations of DM1 (i.e. as part of the under-
lying pathological process), or if they are developed as a 
consequence of living with the disease, or a combination 
of both. Nonetheless, given the prevalence observed in our 
study, mental health in patients with DM1 warrants further 
exploration.
Previous studies [8–10, 17] have estimated mean INQoL 
muscle weakness scores at between 49 and 70, muscle lock-
ing 38 and 63, pain 25 and 42, fatigue 42 and 60, activities 
35 and 55, independence 30 and 47, social relationships 
10 and 23, emotions 24 and 44, body image 6 and 62, and 
total score 19 and 52. Our estimates for the total sample all 
lie within these ranges, with the exception of social rela-
tionships [26], indicating a relatively higher burden on this 
aspect of life in our cohort. However, given the substantial 
variability in estimates (also between patients within sam-
ples), and considering non-trivial differences with respect to 
demographic and clinical characteristics of patients across 
studies, it is likely not meaningful to further compare our 
results. This is also related to the psychometric properties 
of the INQoL, where the Likert scoring algorithm would 
be expected to fail to adhere to the criteria of fundamental 
measurement, which is a requirement for invariant compari-
son [18, 19]. Put differently, although it is clear that a lower/
higher score indicates a lower/higher disease burden, it is not 
clear how a specific score, or differences in scores at vari-
ous points across the scale continuum should be interpreted. 
Indeed, the high association between DM1 symptoms and 
amount and importance of difficulties noted as part of this 
study suggest that combining Likert scores for these items 
may not be appropriate due to non-trivial item dependency. 
The ordinal nature of the INQoL is also likely to affect the 
possibility to detect and interpret changes in total scores 
over time. For example, despite worsening Muscular Impair-
ment Rating Scale (MIRS) outcomes, Peric et al. [17] found 
that total INQoL scores, as well as several subscale scores, 
improved over the course of 6 years. Moreover, in a recent 
multicentre, single-blind, randomised trial, Okkersen et al. 
[20] identified no significant changes in total INQoL scores 
at 10 months from baseline between patients with DM1 
receiving cognitive behavioural therapy plus standard care 
and optional graded exercise and those receiving standard of 
care alone, despite significant changes in the main endpoint 
(i.e. the DM1 activity and participation scale for clinical use 
[DM1-ActivC]) and other secondary endpoints. Additionally, 
Hamilton et al. [21] recently reported some inverse correla-
tions between objective measures of disease severity and 
patient self-reported outcomes, suggesting disease-depend-
ent lack of insight can sometimes mask physical symptoms.
The data presented as part of this study indicate that male 
patients may experience greater impairment in their relation-
ships life compared to their female counterparts. Specifi-
cally, a significantly larger proportion of men (70% vs. 40%) 
reported of difficulties with their friends due to DM1, and 
men with the disease were much less likely to be married 
or in a relationship (36% vs. 70%). Evidence of a relatively 
larger impact on the social life of male patients has been 
reported for DM1 [22], as well as other chronic, disabling 
diseases, such as multiple sclerosis [23], and warrants fur-
ther investigation.
Previous research [24–26] have demonstrated an associa-
tion between CTG repeat length and age at onset in DM1. 
Such age at onset associations have been further improved 
by estimating the progenitor CTG allele length to overcome 
the confounding effects of age-dependent somatic expan-
sion [7]. Previous attempts to correlate CTG length to pro-
gressive phenotypes have typically yielded poorer associa-
tions. Indeed, Antonini et al. [13] and Rakocevic-Stojanovic 
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et al. [10] found no association between quality of life (as 
measured through the SF-36 and INQoL, respectively) and 
CTG repeat length. Here, we have estimated the progeni-
tor CTG allele length to overcome the confounding effects 
of age-dependent somatic expansion and included an age-
CTG interaction to account for the progressive nature of the 
symptoms and the inherent sampling biases found within 
DM1 families (due to the profound anticipation observed in 
DM1, older sampled individuals inherited smaller alleles, 
and vice versa). These analyses have yielded good correla-
tions for overall INQoL score (R2 = 0.19) and for a number 
of the sub-domains: muscle weakness (R2 = 0.21), fatigue 
(R2 = 0.09), muscle locking (R2 = 0.09), activities (R2 = 0.18), 
independence (R2 = 0.23), relationships (R2 = 0.10) and emo-
tions (R2 = 0.12). These data highlight the utility of careful 
genetic and statistical analyses that addresses the sampling 
biases inherent within DM1 populations. Outcome measures 
that are predicted by underlying genetic factors more likely 
to reflect primary disease processes and thus are more likely 
to respond positively to effective therapeutic interventions. 
Conversely, the lack of association with genotype for the 
pain, muscle locking, drooping, double vision, and body 
image scores suggests that these domains are not sensitive 
reporters of the disease process. Genotype to phenotype cor-
relations such as these may therefore be of utility in selecting 
the most informative outcome measures for patient manage-
ment and clinical trials.
Previous studies have also identified unexpected distri-
butions of INQoL scores across measures of disease sever-
ity and age. For example, Peric et al. [17, 27] found that 
worsening of muscular weakness from mild to severe was 
associated with a lower disease burden (i.e. higher quality 
of life). In addition to the sampling biases discussed above, 
potential reasons for these counterintuitive findings include 
lack of disease awareness, in particular in patients with less 
severe disease [8], coping mechanism [28] (which has been 
identified for other rare, neuromuscular diseases, such as 
Duchenne muscular dystrophy [29]), and the properties of 
the scale, as discussed above.
Our study is subject to a few limitations. First, similar 
to most research of patients with rare diseases, our results 
are limited by a relatively small sample, which affects the 
precision and potentially also generalizability of derived 
estimates. This would be expected to be of particular rel-
evance considering the heterogeneous presentation of DM1. 
Additionally, given the underlying variability in outcomes of 
interest and the magnitude of expected differences, conduct-
ing research in small patient populations may also have a 
negative impact on possibilities to perform meaningful eval-
uation of results across subgroups. For this reason, outcomes 
of our testing of differences by, for example, sex should be 
interpreted with some caution. Second, our self-reported 
data may be subjected to bias due to, e.g. incorrect reporting. 
Third, due to the observational nature of our data, we were 
unable to draw conclusions regarding causality. Concerning 
interpretation of results, it is also worth pointing out that we 
were unable to adjust our estimates for patients’ intelligence 
quotient (a variable that may have an impact on how patients 
perceive, and are able to report of, their disease burden), and 
that none of the patients in our sample received cognitive 
behavioural or exercise therapy (which recently have proven 
beneficial for the capacity for activity and social participa-
tion in DM1 [20]).
Conclusions
We show that DM1 is associated with a substantial dis-
ease burden resulting in impairment across many different 
domains of patients’ lives, emphasizing the need for a holis-
tic approach to disease management. Our results also show 
that the INQoL records relevant information about patients 
with DM1, but that further investigation of the psychometric 
properties of the scale is needed for meaningful interpreta-
tion of instrument scores.
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